Volumetric Absorptive Microsampling (VAMS) technology for IGF-1 quantification by automated chemiluminescent immunoassay in dried blood.


Journal

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
ISSN: 1532-2238
Titre abrégé: Growth Horm IGF Res
Pays: Scotland
ID NLM: 9814320

Informations de publication

Date de publication:
02 2020
Historique:
received: 23 07 2019
revised: 23 10 2019
accepted: 06 12 2019
pubmed: 14 12 2019
medline: 17 3 2021
entrez: 14 12 2019
Statut: ppublish

Résumé

For medical diagnostics and anti-doping analyses, insulin-like growth factor 1 (IGF-1) can be measured in serum using automated chemiluminescent immunoassays. The aim of this study was to assess the feasibility of using dried blood instead of serum to measure IGF-1 concentrations with an automated IGF-1 immunoassay and to evaluate if IGF-1 concentrations from dried capillary blood and serum were comparable. Blood samples (venous blood and capillary blood obtained from the arm skin using a device from Seventh Sense Biosystem) were collected with 20 μL Volumetric Absorptive Micro samplers (VAMS) (Mitra®, Neoteryx). These samplers offer the possibility of collecting a fixed volume of blood without perturbation by hematocrit. Starting from dried blood, an aqueous desorption in 0.9% NaCl was efficient to release IGF-1. The solution was directly analyzed on the automated IGF-1 immunoassay. IGF-1 concentrations after extraction from VAMS were lower than in serum (due to the dilution performed for the elution of IGF-1) but measurable for serum concentrations over 50 ng/mL. In addition, IGF-1 on VAMS was stable for at least one month at room temperature. Following adjustment for dilution, serum and dried blood IGF-1 concentrations were of the same order. However lower concentrations were obtained from the capillary blood in particular for high serum concentrations. In conclusion, a micro volume of dried capillary blood could be used to quantify IGF-1 with an automated chemiluminescent immunoassay. However, more data are needed to establish specific IGF-1 reference concentrations using dried capillary blood instead of serum.

Identifiants

pubmed: 31835105
pii: S1096-6374(19)30058-9
doi: 10.1016/j.ghir.2019.12.001
pii:
doi:

Substances chimiques

IGF1 protein, human 0
Insulin-Like Growth Factor I 67763-96-6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

27-34

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Auteurs

A Marchand (A)

Analysis Department, Agence Française de Lutte contre le Dopage (AFLD), 143 avenue Roger Salengro, 92290 Châtenay-Malabry, France. Electronic address: a.marchand@afld.fr.

I Roulland (I)

Analysis Department, Agence Française de Lutte contre le Dopage (AFLD), 143 avenue Roger Salengro, 92290 Châtenay-Malabry, France.

F Semence (F)

Analysis Department, Agence Française de Lutte contre le Dopage (AFLD), 143 avenue Roger Salengro, 92290 Châtenay-Malabry, France.

M Audran (M)

Analysis Department, Agence Française de Lutte contre le Dopage (AFLD), 143 avenue Roger Salengro, 92290 Châtenay-Malabry, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH